What is Oric Pharmaceuticals, Inc.'s stock issuance proceeds?

Oric Pharmaceuticals, Inc. (ORIC) reported stock issuance proceeds of $60.88M in Q1 2026.

What is the long-term trend for Oric Pharmaceuticals, Inc.'s stock issuance proceeds?

Over 2 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s stock issuance proceeds has grown at a 121.1% compound annual growth rate (CAGR), from $50M to $244.37M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Oric Pharmaceuticals, Inc. ORIC Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

ArriVent BioPharma, Inc.AVBP

$54.72M+740%

CG OncologyCGON

$391.55M+57,312%

Olema Pharmaceuticals, Inc.OLMA

$8.43M+3,472%

Inhibrx Biosciences, Inc.INBX

$471K—

Stoke Therapeutics, Inc.STOK

$3.21M+219%

Arcus BiosciencesRCUS

$0-100%

Other financials

Income statement

See full

Operating income-$39.6M-21.1%

Net income-$35.8M-19.1%

EPS (diluted)-$0.34+19.0%

Balance sheet

See full

Cash & equivalents$56.4M+14.3%

Total debt$3.3M+2.6%

Total equity$415.6M+89.1%

Total assets$436.8M+79.8%

Cash flow

See full

Operating cash flow-$32.4M+0.3%

CapEx$2.0K-99.5%

Free cash flow-$32.4M+1.5%

Valuation

See full

Market cap$976.17M+23.0%

Enterprise value$923.07M+23.5%

Returns & leverage

See full

Return on equity-42.6%-4.6pp

Debt / equity0×0.0×

Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s stock issuance proceeds?: Oric Pharmaceuticals, Inc. (ORIC) reported stock issuance proceeds of $60.88M in Q1 2026.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s stock issuance proceeds?: Over 2 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s stock issuance proceeds has grown at a 121.1% compound annual growth rate (CAGR), from $50M to $244.37M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.